Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L9LS for Malaria Prevention in Malian Adults
NCT05816330Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2023
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Plasmodium falciparum malaria comparing L9LS 900 mg with Placebo (2 arms). Primary endpoints: Number of Participants With Local Adverse Events at 7 days, Number of Participants With Systemic Adverse Events at 7 days and 1 more. Started May 2023; status: completed.
02
Drugs
L9LS
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT05816330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05816330.